Filing Details

Accession Number:
0001104659-21-003446
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-01-12 16:16:01
Reporting Period:
2021-01-08
Accepted Time:
2021-01-12 16:16:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1434316 Fate Therapeutics Inc FATE () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1425738 Redmile Group, Llc One Letterman Drive, Building D
Suite D3-300
San Francisco CA 94129
Yes No Yes No
1650527 Jeremy Green C/o Redmile Group, Llc One Letterman
Drive, Building D Suite D3-300
San Francisco CA 94129
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-08 327,485 $85.50 12,957,222 No 4 P Indirect See footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Pre-Funded Warrant to Purchase Common Stock Acquisiton 2021-01-08 257,310 $85.50 257,310 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
257,310 2021-01-08 No 4 P Indirect
Footnotes
  1. These securities are directly owned by certain private investment vehicles and separately managed accounts managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and separately managed accounts. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  2. Michael Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
  3. The pre-funded warrant to purchase common stock of the Issuer has no expiration date.